AN2 Therapeutics (ANTX) Research & Development (2021 - 2026)
AN2 Therapeutics (ANTX) reported Research & Development of $6.7 million for Q1 2026, down 12.31% year-over-year from $7.7 million in Q1 2025, and down 1.98% quarter-over-quarter from $6.9 million in Q4 2025.
AN2 Therapeutics (ANTX) Research & Development (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Research & Development data on file, last reported at $6.7 million in Q1 2026.
- Research & Development for Q1 2026 came in at $6.7 million, down 12.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.8 million (down 28.94% YoY), and the FY2025 annual result was $24.8 million, down 38.82% from the prior year.
- Research & Development declined to $6.7 million in Q1 2026 per ANTX's latest filing, from $6.9 million in the prior quarter.
- Over five years, Research & Development peaked at $14.9 million in Q4 2023 and troughed at $3.2 million in Q2 2025.
- A 5-year average of $9.1 million and a median of $7.7 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 241.6% in 2022, then plunged 73.66% in 2025.
- A 5-year view of Research & Development shows it stood at $8.8 million in 2022, then jumped by 70.46% to $14.9 million in 2023, then slumped by 63.82% to $5.4 million in 2024, then increased by 27.46% to $6.9 million in 2025, then decreased by 1.98% to $6.7 million in 2026.
- Business Quant data shows ANTX's Research & Development at $6.7 million in Q1 2026, $6.9 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -58.00 Mn |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | 6.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.74 Mn |
| Dec 31, 2025 | 6.88 Mn |
| Sep 30, 2025 | 7.00 Mn |
| Jun 30, 2025 | 3.20 Mn |
| Mar 31, 2025 | 7.69 Mn |
| Dec 31, 2024 | 5.40 Mn |
| Sep 30, 2024 | 8.29 Mn |
| Jun 30, 2024 | 12.15 Mn |
| Mar 31, 2024 | 14.66 Mn |
| Dec 31, 2023 | 14.92 Mn |
| Sep 30, 2023 | 14.43 Mn |
| Jun 30, 2023 | 13.54 Mn |
| Mar 31, 2023 | 11.99 Mn |
| Dec 31, 2022 | 8.75 Mn |
| Sep 30, 2022 | 7.43 Mn |
| Jun 30, 2022 | 6.70 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Dec 31, 2021 | 5.31 Mn |
| Sep 30, 2021 | 5.35 Mn |
| Jun 30, 2021 | 3.85 Mn |